Omeros (NASDAQ:OMER) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a buy rating in a report published on Thursday, ValuEngine reports.

OMER has been the topic of a number of other reports. HC Wainwright set a $35.00 price target on Omeros and gave the company a buy rating in a report on Tuesday, May 28th. Wedbush reissued a neutral rating and set a $18.00 target price on shares of Omeros in a research note on Monday, July 15th. Zacks Investment Research cut shares of Omeros from a hold rating to a sell rating in a research note on Wednesday, July 17th. Cantor Fitzgerald began coverage on shares of Omeros in a research note on Monday, May 6th. They set an overweight rating and a $26.00 target price on the stock. Finally, BidaskClub raised shares of Omeros from a sell rating to a hold rating in a research note on Tuesday, July 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $25.80.

OMER traded up $0.07 during trading hours on Thursday, hitting $15.32. The company’s stock had a trading volume of 302,520 shares, compared to its average volume of 420,446. Omeros has a fifty-two week low of $10.30 and a fifty-two week high of $27.00. The stock has a market capitalization of $748.13 million, a price-to-earnings ratio of -6.90 and a beta of 2.98. The business’s 50-day moving average is $15.49.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.04). The company had revenue of $21.80 million during the quarter, compared to analysts’ expectations of $23.18 million. Omeros’s revenue for the quarter was up 1271.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.62) EPS. As a group, equities research analysts forecast that Omeros will post -1.68 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Millennium Management LLC grew its holdings in Omeros by 844.8% during the fourth quarter. Millennium Management LLC now owns 1,112,584 shares of the biopharmaceutical company’s stock worth $12,394,000 after acquiring an additional 994,829 shares during the period. Chicago Equity Partners LLC acquired a new position in shares of Omeros in the 2nd quarter worth $1,094,000. SG Americas Securities LLC grew its holdings in shares of Omeros by 68.5% in the 1st quarter. SG Americas Securities LLC now owns 144,444 shares of the biopharmaceutical company’s stock worth $2,509,000 after acquiring an additional 58,731 shares during the last quarter. Tibra Equities Europe Ltd acquired a new position in shares of Omeros in the 1st quarter worth $771,000. Finally, Geode Capital Management LLC increased its stake in Omeros by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 516,632 shares of the biopharmaceutical company’s stock worth $5,755,000 after purchasing an additional 35,974 shares in the last quarter. Institutional investors own 51.86% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Recommended Story: What is the formula for calculating total return?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.